RxDoctor Payments Data

Crystal Holden

Nurse Practitioner · Fort Worth, TXNPI 1922659531

Payments from drug & device makers

$1,816in general payments, 2019–2025

Across 62 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$399
  • Novo Nordisk$368
  • Dexcom, Inc.$141
  • GSK$137
  • Astellas Pharma US Inc$130
  • AbbVie$125
  • plus $515 from 11 others

What the payments were for

  • Food & beverage$1,73696%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,816 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$62,194
Medicare patients
175
Services billed
1,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$109,464
FarxigaDapagliflozin Propanediol23$29,018
JardianceEmpagliflozin22$27,359
MyrbetriqMirabegron19$19,450
SynthroidLevothyroxine Sodium34$2,931
SymbicortBudesonide/Formoterol Fumarate12$2,743
Alendronate Sodium31$1,824
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,662
Bupropion XlBupropion Hcl56$1,327
Gabapentin49$1,257
Levothyroxine Sodium122$893
Estradiol37$835
Rosuvastatin Calcium108$825
Ropinirole Hcl24$745
Celecoxib13$738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$368$109,464102 claims
AstraZenecaFarxiga, Symbicort$399$31,76035 claims
Astellas Pharma US IncMyrbetriq$130$19,45019 claims
AbbVieSynthroid$125$2,93134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →